You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates

    SBC: APOIMMUNE, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Lentiviral gene therapy for mucopolysaccharidosis

    SBC: LENTIGEN CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive inherited disorder caused by absence of iduronate-2-sulfatase, resulting in systemic accumulation of glycosaminoglycans heparan sulphate and dermatan sulphate. Affected individuals suffer from skeletal abnormalities, organomegaly, life- threatening obstructive airway disease, and, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO

    SBC: EYERX RESEARCH, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Over the past sixty years, antibiotics have comprised a key component in both the treatment and prophylaxis of bacterial infections. Since that time the continuous development of new antibiotics has been necessary to limit toxicity, promote broader spectrum therapy, increase convenience of use, and decrease the time to clear the infection. Another driving force ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Learning System for Continuous Professional Education in Low Vision Rehabilitatio

    SBC: Emerald Events, Inc.            Topic: NEI

    Emerald Education Systems has developed an online continuing professional education learning system that targets low vision rehabilitation service providers. This CE learning system has three components: 1) a set of coordinated in depth online courses that provide a broad and deep foundation of knowledge on low vision rehabilitation that is delivered using a didactic approach at a learner-controll ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Improve Wound Healing with HIF-CA5 DNA Vector and Electroporation

    SBC: CANTON BIOTECHNOLOGIES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Therapy to Improve Wound Healing with DNA Expression Vector for HIF 11 and Electroporation Impaired wound healing is a tremendous problem for individuals with diabetes. Patients with diabetes are at risk for developing foot ulcers. These non-healing ulcerations on the foot are disabling, and their progression leads to amputation of the lower extremity. Diabetes ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. In Vivo Assessment of Embryonic Stem Cell Teratoma Prevention

    SBC: BIOINVISION INC            Topic: NICHD

    DESCRIPTION (provided by applicant): The capacity to evaluate the teratoma forming potential of differentiated embryonic stem cell populations represents an urgent need before widespread therapeutic application of these cells is possible. Researchers at Case Western Reserve University and BioInVision, Inc. will join together to create platform technologies for validating existing embryonic stem ce ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Sensor Network for Monitoring Real-world Arm Activity of Rehabilitation Patients

    SBC: ACTIVE WAVE, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Evidence and theory indicate that laboratory measures of impairment and function do not predict how older adults actually function in daily life. Thomas Glass (1998), for example, reports marked differences between functional activities that community residents can do and do do in survey data from the MacArthur Studies of Successful Aging. Therefore, subst ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Vaginal Ring for Preventing Bacterial Vaginosis

    SBC: REPROTECT, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Bacterial Vaginosis (BV) is an exceptionally common vaginal condition in which robust lactobacillus microflora in the vagina is replaced by a dense polymicrobial overgrowth. At any given time, about 1 in 3 women in the U.S. have BV; half are asymptomatic, and most women with symptomatic BV have only mild symptoms (increased discharge with a fishy smell). Despit ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting endothelial arginase to treat diabetes-associated vascular dysfunction

    SBC: ARGINETIX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Small Molecule targeting of NADPH oxidase in neutrophils

    SBC: P2D, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events including major surgery, trauma, multiple transfusions and sepsis. ALI/ARDS have an associated mortality of 40-80% and current pharmacological modalities have been unsuccessful in decreasing mortality. ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government